article thumbnail

2024 IDstewardship Year End Review

IDStewardship

It is likely our newsletter will remain a key communication for reaching the IDstewardship community.Not knowing what 2025 will hold, it is likely unpredictable events in our future will further guide what activities we engage in this year. Steven Smoke, Pharm.D., It is likely there will be greater activity on Bluesky and less activity on X.

article thumbnail

GSK’s world-first gonorrhoea vaccine launched in England

Pharmaceutical Technology

Robert Barrie August 5, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook In 2023, a record 85,000 cases of the disease were reported in England — three times higher than in 2012. In 2023, a record 85,000 cases of the disease were reported in England — three times higher than in 2012.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Best statin therapy for diabetes

The Checkup by Singlecare

In 2012, the Food and Drug Administration (FDA) announced that all statins should carry a warning about their potential to increase fasting blood sugar and hemoglobin A1c (HbA1c) levels in people who take them. Talk to your healthcare provider if you notice any new symptoms or have concerns about your blood sugar while taking a statin.

article thumbnail

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

The National Institutes of Health reports that in 2012, $418 billion was wasted in the US due to suboptimal use of medications. If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. compared with $546,082.45 for the external mail-order pharmacies.

article thumbnail

Alfasigma sets stage for Jyseleca in axSpA after Phase III win

Pharmaceutical Technology

The first partnership with the therapy was between original developer Galapagos and Abbot Laboratories in 2012, when the therapy was in Phase II development in RA. Jyseleca in third development partnership The development of Jyseleca has seen several shifts in the pharmaceutical industry.

article thumbnail

Medication Adherence in 2025: The Hidden Crisis Costing Lives and Billions

PharmD Live

New England Journal of Medicine, 365 (21), 2002–2012. CDC Grand Rounds: Improving medication adherence for chronic disease management—innovations and opportunities.  Morbidity and Mortality Weekly Report, 66 (45), 1248–1251.   [link] Benjamin, R. Medication adherence: Helping patients take their medicines as directed. link] (PMC No. 3234383).

article thumbnail

FDA creates new priority review voucher scheme to boost US interests

Pharmaceutical Technology

The PRV programme for rare paediatric diseases, signed into law in 2012, expired in late 2024 after it failed to make it into a US Congress funding package. PRVs are currently handed out for pharma companies developing treatments for rare paediatric diseases, neglected tropical diseases, and material threat medical countermeasures.

FDA